Articles tagged with Prostate Cancer
Using combination therapies that include 6 months of androgen suppression therapy (AST) alongside radiation therapy (RT) improves survival rates for patients with locally advanced prostate cancer. The study found significantly higher survival rates, lower prostate cancer-specific mortality, and a reduced need for salvage AST in the com...
Researchers have identified strong evidence for a prostate cancer gene on chromosome 17, which is also known to harbor the breast cancer gene BRCA1. A separate study found that a variant of the MIC-1 gene, involved in inflammation, is associated with a decreased risk for prostate cancer.
Researchers found that prostate cancer cells shed immunostimulatory molecules, allowing them to evade the immune system's natural killer cell defense. Soluble MIC levels in serum correlated with high-grade and invasive tumor status, suggesting a potential biomarker for disease progression.
Researchers have discovered a new gene, EphB2, that plays a critical role in regulating tissue organization and maintaining normal cell behavior. The study found that this gene is inactivated in prostate cancer cells, leading to disorganization and tumor growth.
Thomas Jefferson University is developing a clinical trial using a bone-targeted agent to treat microscopic bony metastasis in high-risk prostate cancer patients. The trial aims to improve death rates from prostate cancer by combining hormones and radiation with the targeted agent, Quadramet.
Researchers found DNA and proteins from BK virus in prostate tissue with abnormal cell changes, a precursor stage of prostate cancer. The virus may induce uncontrolled cell growth, leading to cancer.
A new study by Mount Sinai School of Medicine researchers found that combining three therapeutic modalities increases the percentage of high-risk patients who are free from recurrence after five years. A three-pronged approach that included brachytherapy, external beam radiation therapy and hormonal therapy produced an 86 percent rate ...
Researchers identified 671 genes with altered expression in prostate cancer tissue, revealing a high degree of similarity between benign adjacent tissue and cancerous tissue. The study found that genetic alterations occur throughout the gland, even in seemingly benign areas, providing new insights into prostate cancer progression.
A recent study found a significant correlation between active Stat5 protein and high-grade prostate cancer. The research suggests that blocking the signals that turn on Stat5 may lead to effective treatment strategies for advanced prostate cancer.
Two projects aim to study angiogenesis and anti-angiogenic therapy, as well as the interaction between hormones and growth factors in prostate tumor growth. The ultimate goal is to develop new treatment strategies that suppress metastases by prolonging dormant states.
A study published in NEJM found that rapid rise in PSA levels prior to diagnosis is a stronger indicator of prostate cancer death than the actual PSA level. Early and annual testing are recommended for men with high PSA velocity to detect potential aggressiveness of cancers.
Researchers found that bicalutamide treatment resulted in increased bone mineral density, reduced body fat, and fewer side effects compared to leuprolide. This study suggests a single-drug treatment plan using bicalutamide may be an attractive alternative for men with non-metastatic prostate cancer.
A new study suggests that early hormone therapy can increase survival time by up to 14 years for men with aggressive prostate cancer, compared to those who delay treatment. Prostate cancer affects over 220,000 men annually in the US, with approximately 30,000 dying from the disease each year.
Researchers found that Cox-2 inhibitors slowed disease progression in men with recurrent prostate cancer by inhibiting tumor growth and increasing programmed cell death. The study showed significant results in 22 of 24 patients, with a 92% reduction in PSA levels after three months.
A study of 223 patients with early-stage, initially untreated prostate cancer found that disease progression increased significantly after 15 years of follow-up. After 10-15 years, most cancers had an indolent course, but progression rates decreased over time.
A global study led by Johns Hopkins Medicine found that docetaxel therapy significantly improves survival time for hormone-resistant prostate cancer patients. Patients treated with tri-weekly docetaxel survived 2.4 months longer than those receiving the standard chemotherapy drug, mitoxantrone.
Two landmark studies show that Taxotere-based regimens improve patients' PSA responses by 43% and pain responses by 59%, leading to a 27% increase in disease-progression-free survival. The treatment also provides hope to thousands of men worldwide, offering an important new option for living longer.
A new study shows that estrogen skin patches can counteract high cholesterol associated with hormone therapy for prostate cancer. The patches decreased overall cholesterol levels by 10 percent and increased good cholesterol (HDL), while also improving lipid profiles.
Researchers found four distinct risk groups and seven independent risk factors for prostate cancer detection, including abnormal exam findings, age, family history, and PSA density. Men with high-risk features remain at risk despite multiple negative biopsies, emphasizing the need for vigilant follow-up.
A new study finds that estrogen therapy significantly improves verbal memory performance in men with advanced prostate cancer, while hormone deprivation impairs it. Estrogen also reduces depression and confusion in these patients.
A new study found that hormone deprivation therapy is less effective for younger men with higher grade tumors, suggesting it needs further investigation as an alternative treatment for localized prostate cancer. The study also revealed a higher risk of bone fractures in men on hormone therapy due to osteoporosis.
A new study suggests that men who take statins, common cholesterol-lowering drugs, have a significantly reduced risk of prostate cancer. Statin use was associated with a 58% lower risk of prostate cancer and a 55% lower risk of elevated PSA levels.
A new medication called atrasentan has shown promise in slowing the progression of prostate cancer to the bone, reducing pain and maintaining quality of life. The drug's effect on stabilizing disease progression was observed across phase II and III clinical trials.
Researchers explore alternative biomarkers for prostate cancer using immune responses to AMACR, while a new RNA interference strategy shows potential in silencing PLK1 genes. The latest AJCC breast cancer staging system revision also influences false-negative rates.
Researchers developed two treatments to minimize nerve damage and facilitate nerve recovery, preserving ability to have an erection after radical prostatectomy. Muscle-derived cells and glial cell-derived neurotrophic factors improved erectile function in animal models with cavernous nerve injury.
A study by Mount Sinai School of Medicine found that brachytherapy effectively treats prostate cancer while preserving quality of life. The research team followed 255 patients with prostate cancer treated with I-125 and reported minimal urinary symptoms, preserved potency, and reduced bleeding.
Researchers found that quality of life for men treated for prostate cancer continues to evolve long-term, with some experiencing improvements and others worsening. Sexual function remains a significant concern for survivors, with reported lower quality of life compared to non-cancerous individuals.
Moderately and severely obese patients experienced higher Gleason scores and rising PSA levels after surgery, indicating aggressive prostate cancer. Men with a BMI of greater than 35 kg/m2 had a 60% risk of cancer recurrence within three years.
A UMHS study found that African-American men with a history of gonorrhea are more likely to develop prostate cancer. The research suggests an inflammatory effect from the bacterial infection may trigger pre-existing cancerous cells to multiply, increasing risk.
Researchers found a significant association between high blood testosterone levels and an increased risk of prostate cancer in older men. The study, which followed over 3,000 men for 40 years, also showed that the protein sex hormone-binding globulin (SHBG) was associated with a slightly decreased risk for prostate cancer.
Researchers have identified a new biomarker, EPCA, which may enable early detection and treatment of prostate cancer. The study found that EPCA was expressed in tissue samples from patients with prostate cancer who initially had negative biopsies.
A study found that over half of men taking part in a prostate cancer risk assessment program reported using dietary supplements to prevent the disease. The most commonly used supplements were vitamins and minerals, with saw-palmetto being one popular option.
A University of Michigan study found that most prostate cancer treatment guides overlook key details and favor active treatment over watchful waiting. The researchers recommend complete information on risks and benefits, clear writing styles, and visual elements to engage readers.
A study confirmed that BRCA2 mutations are linked to prostate cancer, with a risk 4.8 times higher than in healthy individuals. The results suggest that prostate cancer screening may begin at age 50 for men carrying these mutations.
A study found that black men with prostate cancer are more likely to die from the disease due to delayed or inadequate care, particularly those without other diagnosed illnesses. The researchers suggest that cultural and social factors contribute to this disparity.
A study found that men who consumed green and black tea for five days had slower-growing prostate cancer cells compared to those who drank diet or regular soda. The researchers discovered a significant negative correlation between total polyamine levels and tea polyphenol content in the tissue.
A new online tool provides personalized 10-year survival predictions for prostate cancer patients, taking into account age, race, co-morbidities, and treatment type. The model also highlights the significant impact of co-morbidities on long-term survival rates.
Prostate cancer cell lines exhibit high levels of free radical damage and defective repair mechanisms, leading to a cascade of events culminating in further DNA damage and cellular dysfunction. The new research provides solid evidence for the critical role of free radicals and repair in prostate cancer development.
A large cohort study found no association between ejaculation frequency and increased prostate cancer risk. High ejaculation frequency may actually be associated with a lower risk of total and organ-confined prostate cancer.
Researchers found that men with a family history of prostate cancer can accurately assess their lifetime risk and are more likely to use supplements to improve their health. The study also reveals that younger brothers of men with prostate cancer are nearly four times more likely to report using complementary or alternative medicine.
A study found that equol, a natural metabolite from soy isoflavones, blocks the effects of DHT without altering testosterone levels, reducing prostate size in rats. This molecule may offer a treatment for BPH and prostate cancer, as well as promoting healthy skin and hair growth.
A recent UMHS study found that black men with moderate-grade prostate cancer are 36% less likely to receive treatment than white men. Hispanic men also face disparities in treatment, with 16% fewer chances of receiving definitive therapy compared to white men.
A team of scientists at Rutgers University has identified the active compound in croton plant oil, TPA, which shows promise in treating prostate cancer. The study found that TPA can stop new cells from growing, kill existing cancer cells, and shrink prostate tumors.
A study of 501 patients with recurrent prostate cancer found that salvage radiotherapy can be effective for patients with high-grade disease and rapid PSA doubling time, suggesting it may prevent metastatic disease progression. The study's findings support early treatment for these patients, who are at the highest risk of disease spread.
Researchers have developed a gene expression profiling method that predicts clinical outcome in prostate cancer patients. The study's findings suggest that this approach can improve our ability to stratify patient populations and optimize disease treatment.
A new biomarker, EPCA, has been discovered that can detect prostate cancer earlier than traditional methods. The marker is expressed in the tumor and throughout the prostate in men with prostate cancer.
The new guidelines recommend limiting treatment to patients at expected risk for metastatic disease and only evaluating drugs with demonstrated clinical activity. The guidelines also require significant proportion of patients to show decline or no increase in PSA and prostate-cancer specific survival.
A comprehensive review of 72 studies found no evidence that testosterone replacement therapy increases prostate cancer or cardiovascular disease risk. Testosterone therapy may alleviate symptoms of low testosterone levels, but monitoring is crucial due to potential side effects.
Two studies found obesity increases risk of aggressive prostate cancer and cancer recurrence in African-American men. Obesity is associated with higher Gleason scores and elevated PSA levels, suggesting a link between excess body fat and tumor growth.
A study led by Rutgers University professor Mohamed Rafi founds a compound called ß-hydroxy-DHP (BHP) in licorice root supplements that can stop the growth of prostate and breast cancer cells. This could provide new hope for more effective therapies against these leading cancers.
Researchers are investigating the role of broccoli-derived chemicals in preventing prostate cancer. The study aims to better understand how these substances inhibit prostate cancer growth and identify potential biomarkers for future intervention trials.
A new study finds that older men with healthy life expectancy are less likely to receive adequate cancer treatment than younger patients. Despite better prognosis, older prostate cancer patients may not receive important treatments that could extend their life.
A study found that 29.8% of Ontario men diagnosed with prostate cancer used complementary medicine, highlighting the need for awareness and discussion among clinicians. The most commonly used products were natural health supplements like vitamin E, saw palmetto, and selenium, which may interact with conventional therapies.
Researchers found that c-myc promotes androgen-independent growth in prostate cancer cells, slowing growth with downregulation. This suggests a physiological role for c-myc in prostate cancer and offers a possible therapeutic target.
A study of 33 elderly men with advanced prostate cancer found that external beam radiation therapy was well-tolerated and effective in keeping the cancer at bay. The patients experienced no unusual interruptions in treatment due to illness from radiation, and many remained alive and disease-free for several years.
Researchers found that black patients undergoing surgery had a median survival time 1.8 years less than white patients, with disparities smaller among radiation therapy and non-aggressive therapy groups. The study suggests genetic and environmental factors may contribute to these racial disparities in prostate cancer treatment outcomes.
A new campaign, SELECT Sunday, aims to raise awareness of prostate cancer among African-American men, who have the highest incidence rates and a death rate more than double that of white men. The campaign seeks to double African-American enrollment in an international study investigating vitamin E and selenium as preventive measures.
Researchers at Ohio State University Comprehensive Cancer Center found that a diet rich in whole tomatoes, but not supplements, was associated with longer survival rates and reduced risk of prostate cancer. The study also showed that energy restriction did not offer additional benefits over a balanced diet.
A study published in the Journal of the National Cancer Institute found that rats fed whole tomato powder had a 26% lower risk of prostate cancer death compared to those on control diets. The researchers suggest that whole tomato products and energy balance may offer independent benefits against prostate cancer.
A recent study suggests that lycopene's anti-cancer effect is enhanced by other compounds in tomatoes, such as phytochemicals. Whole tomato consumption was found to offer a lower risk of prostate cancer death compared to dietary supplements.